These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 688611)

  • 61. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Spectrophotometric, spectrofluorometric and HPLC determination of desloratadine in dosage forms and human plasma.
    El-Enany N; El-Sherbiny D; Belal F
    Chem Pharm Bull (Tokyo); 2007 Dec; 55(12):1662-70. PubMed ID: 18057737
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women.
    Furlanut M; Franceschi L; Pasqual E; Bacchetti S; Poz D; Giorda G; Cagol P
    Ther Drug Monit; 2007 Jun; 29(3):349-52. PubMed ID: 17529893
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Fast method for simultaneous quantification of tamoxifen and metabolites in dried blood spots using an entry level LC-MS/MS system.
    Tré-Hardy M; Capron A; Antunes MV; Linden R; Wallemacq P
    Clin Biochem; 2016 Nov; 49(16-17):1295-1298. PubMed ID: 27498307
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Determination of tamoxifen and metabolites in human serum by high-performance liquid chromatography with post-column fluorescence activation.
    Brown RR; Bain R; Jordan VC
    J Chromatogr; 1983 Feb; 272(2):351-8. PubMed ID: 6833432
    [TBL] [Abstract][Full Text] [Related]  

  • 66. New approach based on immunochemical techniques for monitoring of selective estrogen receptor modulators (SERMs) in human urine.
    Salvador JP; Vila-Roca E; Monfort N; Ventura R; Marco MP
    J Pharm Biomed Anal; 2018 Jul; 156():147-152. PubMed ID: 29704771
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques.
    Teunissen SF; Rosing H; Seoane MD; Brunsveld L; Schellens JH; Schinkel AH; Beijnen JH
    J Pharm Biomed Anal; 2011 Jun; 55(3):518-26. PubMed ID: 21392921
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations.
    Lawrence JA; Adamson PC; Caruso R; Chow C; Kleiner D; Murphy RF; Venzon DJ; Shovlin M; Noone M; Merino M; Cowan KH; Kaiser M; O'Shaughnessy J; Zujewski J
    J Clin Oncol; 2001 May; 19(10):2754-63. PubMed ID: 11352969
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels.
    de Vos D; Slee PH; Briggs RJ; Stevenson D
    Cancer Chemother Pharmacol; 1998; 42(6):512-4. PubMed ID: 9788580
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.
    Lien EA; Wester K; Lønning PE; Solheim E; Ueland PM
    Br J Cancer; 1991 Apr; 63(4):641-5. PubMed ID: 2021551
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fast and Adequate Liquid Chromatography-Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring.
    de Krou S; Rosing H; Nuijen B; Schellens JH; Beijnen JH
    Ther Drug Monit; 2017 Apr; 39(2):132-137. PubMed ID: 28045782
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care.
    Jager NG; Rosing H; Schellens JH; Linn SC; Beijnen JH
    Breast Cancer Res Treat; 2014 Feb; 143(3):477-83. PubMed ID: 24390246
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Development, validation and clinical application of a HPLC-FL method for CYP2D6 phenotyping in South Brazilian breast cancer patients.
    Antunes MV; Staudt DE; Raymundo S; de Oliveira V; Gössling G; Pirolli R; Biazús JV; Cavalheiro JA; Rosa DD; Schwartsmann G; Linden R
    Clin Biochem; 2014 Aug; 47(12):1084-90. PubMed ID: 24747158
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Elevated plasma tamoxifen levels in a patient with liver obstruction.
    DeGregorio MW; Wiebe VJ; Venook AP; Holleran WM
    Cancer Chemother Pharmacol; 1989; 23(3):194-5. PubMed ID: 2924377
    [No Abstract]   [Full Text] [Related]  

  • 75. Synthesis of a coumarin compound from phenanthrene by a TiO2-photocatalyzed reaction.
    Higashida S; Harada A; Kawakatsu R; Fujiwara N; Matsumura M
    Chem Commun (Camb); 2006 Jul; (26):2804-6. PubMed ID: 17009469
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Tamoxifen-Loaded Eudragit Nanoparticles: Quality by Design Approach for Optimization of Nanoparticles as Delivery System.
    Khattak MA; Iqbal Z; Nasir F; Neau SH; Khan SI; Hidayatullah T; Pervez S; Sakhi M; Zainab SR; Gohar S; Alasmari F; Rahman A; Maryam GE; Tahir A
    Pharmaceutics; 2023 Sep; 15(10):. PubMed ID: 37896131
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Photoactivatable Fluorophores for Bioimaging Applications.
    Zhang Y; Zheng Y; Tomassini A; Singh AK; Raymo FM
    ACS Appl Opt Mater; 2023 Mar; 1(3):640-651. PubMed ID: 37601830
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of tamoxifen and metabolites by LC-MS/MS and HPLC methods.
    Heath DD; Flat SW; Wu AH; Pruitt MA; Rock CL
    Br J Biomed Sci; 2014; 71(1):33-9. PubMed ID: 24693573
    [TBL] [Abstract][Full Text] [Related]  

  • 79. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.
    Jordan VC
    Steroids; 2007 Nov; 72(13):829-42. PubMed ID: 17765940
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.
    Jordan VC
    Breast Cancer Res Treat; 1983; 3 Suppl():S73-86. PubMed ID: 6423014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.